The APOBEC3C Knockout KYSE-30 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for functional investigation of APOBEC3C in a human esophageal squamous cell carcinoma background. This product enables loss-of-function experiments through CRISPR/Cas9-mediated target-gene disruption, yielding a heterogeneous pool of knockout cells that can be utilized directly for downstream assays or further subcloned for clonal expansion.
The KYSE-30 cell line is an epithelial model derived from a well-differentiated esophageal squamous cell carcinoma of a 64-year-old male. It faithfully retains morphological and molecular features of esophageal squamous epithelium and is extensively used to study esophageal cancer pathogenesis, including tumorigenic mechanisms, drug responses, and intracellular signaling networks.
APOBEC3C is a cytidine deaminase that restricts retroviruses and retrotransposons by deaminating cytidine to uridine in single-stranded DNA. Its expression is upregulated by interferon signaling via STAT1 and IRF transcription factors, and it responds to cytokines such as TNF-?? and IL-6. APOBEC3C interacts with HIV-1 Vif, which mediates its degradation, and with AGO2 and RNA-binding proteins that modulate its activity. The resulting uracil lesions are repaired by UNG and SMUG1, while unresolved damage activates ATR and ATM, linking the enzyme to the DNA damage response.
In esophageal squamous cell carcinoma, aberrant APOBEC3C expression is postulated to fuel mutation accumulation and tumor heterogeneity. This polyclonal knockout model allows precise dissection of APOBEC3C??s contributions to mutational signatures, DNA damage signaling, and innate immune pathways in a disease-appropriate cellular context. By eliminating APOBEC3C, researchers can evaluate its role in driving genomic instability and assess its potential as a therapeutic vulnerability.
These cells are suitable for a broad range of experimental approaches, including mutation signature analysis via whole-genome sequencing, viral infectivity assays, and DNA damage assessment using ??H2AX foci detection. Other applications encompass western blotting, RT-qPCR, immunofluorescence, flow cytometry, co-immunoprecipitation with HIV-1 Vif, and drug sensitivity profiling. The polyclonal nature of the population provides a robust platform for functional genomics in esophageal cancer and can serve as a source for generating monoclonal derivative lines if desired. For additional information or to discuss project-specific requirements, please contact Ascent Research.
